Equity Digest Directory
  Advanced Search
Exchanges
 
 
Equity Digest Stock Directory / OTC / View Listing

NVLX Nuvilex Inc

http://nuvilex.com/
Title: NVLX Nuvilex Inc
Category: OTC
Listing added: Apr 22, 2012
NVLX OTC BB Nuvilex Inc
Fields
 
SYMB Company Name: NVLX OTC BB Nuvilex Inc

Nuvilex OTCQB: NVLX 
Announces Major Breakthrough in Stem Cell Research

As Highlighted in Goldman Research Report Nuvilex Stem Cell Technology
Allows for Replication Without Rejection or Migration from Targeted Site

NUVILEX, INC. OTCBB: NVLX - .064 NVLX represents one of the most remarkable investments in health care in decades. If Steve Jobs only knew about NVLX technology, he might still be with us today!

At current prices, given its level of innovation, buying NVLX stock is like buying 3 stocks for the price of 1. NVLX, through its pending acquisition of SG Austria, utilizes a proprietary, cutting-edge technology for improving existing treatments for cancer and diabetes, and for stem cell use.

Goldman Update Report

Most companies only have expertise in one treatment category. NVLX, investors have an opportunity to buy stock inwhat will likely become one of the leading companies treating cancer, diabetes, and stem cell utilization. Since the NVLX delivery system can be used in so many therapies, the market opportunity is in the tens of billions, and leading drug companies will likely partner or license technology from NVLX to improve their own drugs and maintain their market shares. The stock may be on the verge of an explosive upsurge due to its blockbuster cell encapsulated technology.
Last Trade: Date 20-Apr-12 Open $0.0530 High $0.0660 Low $0.0530 Close $0.0640 Vol 1922100
Week: High $0.0710 Low $0.0550 Chg $0.0110 AvChg Vol 1,149,840
Month: High $0.0890 Low $0.0280 Chg $0.0225 AvChg $0.0013 Vol 1,916,780
Year: MA5 $0.0603 MA20 $0.0605 MA50 $0.0432 MA100 $0.0452 MA200 $0.0498
 
Very Bottom Banners
 
 
 
About Us | Privacy Policy | Terms of Use | Help | Tag Cloud | Tell Friend | Contact Us
© 2012 Powered by EQD ePublications & Mobi Market Solutions Editor: Samuel Lozano